Cyclo-RGDfK is an effective cytoskeleton inhibitor, that has the ability to prevent the pathway of cytoskeletal signaling by inhibiting integrin. It targets the αvβ3.
Molecular Weight
603.7
Molecular Formula
C27H41N9O7
Targets
αvβ3: 0.94 nM (IC50)
Form
Lyophilized powder
Purity
≥98%
Titer
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects
Applications
Cyclo-RGDfK is a cytoskeletal signaling inhibitor that can be studied extensively for its potential therapeutic applications in the treatment of cancer and other diseases involving aberrant cell adhesion and migration.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.